Literature DB >> 21199697

Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.

Shixia Wang1, Jon D Goguen, Fusheng Li, Shan Lu.   

Abstract

Yersinia pestis (Y. pestis) is the causative pathogen of plague, a highly fatal disease for which an effective vaccine, especially against mucosal transmission, is still not available. Like many bacterial infections, antigen-specific antibody responses have been traditionally considered critical, if not solely responsible, for vaccine-induced protection against Y. pestis. Studies in recent years have suggested the importance of T cell immune responses against Y. pestis infection but information is still limited about the details of Y. pestis antigen-specific T cell immune responses. In current report, studies are conducted to identify the presence of CD8+ T cell epitopes in LcrV protein, the leading antigen of plague vaccine development. Furthermore, depletion of CD8+ T cells in LcrV DNA vaccinated Balb/C mice led to reduced protection against lethal intranasal challenge of Y. pestis. These findings establish that an LcrV DNA vaccine is able to elicit CD8+ T cell immune responses against specific epitopes of this key plague antigen and that a CD8+ T cell immune response is involved in LcrV DNA vaccine-elicited protection. Future studies in plague vaccine development will need to examine if the presence of detectable T cell immune responses, in particular CD8+ T-cell immune responses, will enhance the protection against Y. pestis in higher animal species or humans.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21199697      PMCID: PMC3079781          DOI: 10.1016/j.vaccine.2010.12.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  56 in total

1.  Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.

Authors:  E D Williamson; A J Stagg; S M Eley; R Taylor; M Green; S M Jones; R W Titball
Journal:  Vaccine       Date:  2006-10-02       Impact factor: 3.641

Review 2.  Plague immunization. I. Past and present trends.

Authors:  K F Meyer; D C Cavanaugh; P J Bartelloni; J D Marshall
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

3.  Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system.

Authors:  Shixia Wang; Te-hui W Chou; Pavlo V Sakhatskyy; Song Huang; John M Lawrence; Hong Cao; Xiaoyun Huang; Shan Lu
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy.

Authors:  J E Eyles; E D Williamson; I D Spiers; H O Alpar
Journal:  Vaccine       Date:  2000-08-01       Impact factor: 3.641

5.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.

Authors:  B S Graham; L A Bunton; P F Wright; D T Karzon
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

6.  Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha.

Authors:  R Nakajima; R R Brubaker
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

Review 7.  Current challenges in the development of vaccines for pneumonic plague.

Authors:  Stephen T Smiley
Journal:  Expert Rev Vaccines       Date:  2008-03       Impact factor: 5.217

8.  Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague.

Authors:  S E Leary; E D Williamson; K F Griffin; P Russell; S M Eley; R W Titball
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

9.  Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens.

Authors:  Audrey Glynn; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2005-03-14       Impact factor: 3.641

10.  Cellular and humoral immunity against vaccinia virus infection of mice.

Authors:  Rong Xu; Aaron J Johnson; Denny Liggitt; Michael J Bevan
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more
  15 in total

1.  Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Aaron Wallace; Kim West; Alan L Rothman; Francis A Ennis; Shan Lu; Shixia Wang
Journal:  Hum Vaccin Immunother       Date:  2013-08-13       Impact factor: 3.452

2.  Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague.

Authors:  Wei Sun; Shilpa Sanapala; Hannah Rahav; Roy Curtiss
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

3.  LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Authors:  Wei Sun; Shilpa Sanapala; Jeremy C Henderson; Shandiin Sam; Joseph Olinzock; M Stephen Trent; Roy Curtiss
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

4.  Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague.

Authors:  Jr-Shiuan Lin; Frank M Szaba; Lawrence W Kummer; Brett A Chromy; Stephen T Smiley
Journal:  J Immunol       Date:  2011-06-08       Impact factor: 5.422

5.  Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.

Authors:  Anthony J Hickey; Jr-Shiuan Lin; Lawrence W Kummer; Frank M Szaba; Debra K Duso; Michael Tighe; Michelle A Parent; Stephen T Smiley
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

6.  Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.

Authors:  William Bowen; Lalit Batra; Amanda R Pulsifer; Esma S Yolcu; Matthew B Lawrenz; Haval Shirwan
Journal:  Vaccine       Date:  2019-08-12       Impact factor: 3.641

Review 7.  Plague Vaccines: Status and Future.

Authors:  Wei Sun
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 8.  Plague vaccines: current developments and future perspectives.

Authors:  Valentina A Feodorova; Vladimir L Motin
Journal:  Emerg Microbes Infect       Date:  2012-11-07       Impact factor: 7.163

9.  Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine.

Authors:  Wei Li; Shixia Wang; Shan Lu
Journal:  Vaccines (Basel)       Date:  2013-12-27

10.  Depletion of CD8+ T cells from vaccinated goats does not affect protection from challenge with wild-type peste des petits ruminants virus.

Authors:  Michael D Baron; Sophia Hodgson; Katy Moffat; Mehnaz Qureshi; Simon P Graham; Karin E Darpel
Journal:  Transbound Emerg Dis       Date:  2020-12-20       Impact factor: 4.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.